ContractProduct Specific Agreement • March 1st, 2021 • Fibrogen Inc • Pharmaceutical preparations
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would likely cause competitive harm to the company if publicly disclosed.
MASTER SERVICES AGREEMENT between SAMSUNG BIOLOGICS CO., LTD. and FIBROGEN, INC.Master Services Agreement • March 1st, 2021 • Fibrogen Inc • Pharmaceutical preparations • New York
This Master Services Agreement (this “MSA”) is entered into as of the date of the last signature below, and is effective as of October 30, 2020 (the “Effective Date”) by and between FibroGen, Inc., a Delaware corporation having its principal place of business at 409 Illinois Street, San Francisco, California, USA 94158 (“Client”), and Samsung Biologics Co., Ltd., a company with offices at [*] (“SBL”). Client and SBL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
